Compare ACM Research Inc (ACMR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACM Research Inc vs GeneDx Holdings Corp — how do they compare? ACM Research Inc trades at $98.15 (market cap $6.54B), while GeneDx Holdings Corp trades at $65 (market cap $1.94B). The key difference: ACM Research Inc is far larger — about 3.4× GeneDx Holdings Corp's market cap, and ACM Research Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| ACMR | WGS | |
|---|---|---|
Market Cap | $6.54B | $1.94B |
Sector | Technology | Technology |
52-Week High | $126.89 | $167.51 |
52-Week Low | $23.92 | $34.51 |
Enterprise Value | $5.61B | $1.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $98.52, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $110. Recent earnings showed a Q1 2026 beat but misses in prior quarters. Revenue grew to $901 million in 2025, though net income margins are under pressure. The stock has experienced volatility, with news highlighting semiconductor sector catalysts and a GF Score of 82 (GuruFocus, June 25, 2026).
Outlook is positive with 80% analyst buy ratings and semiconductor demand tailwinds, but risks include earnings inconsistency, high valuation multiples, and negative operating cash flow. Investors should weigh growth potential against execution risks in a competitive market.
GeneDx Holdings Corp. (WGS) trades at $68.89, up 2.04% today, with a bullish technical signal from moving averages and a consensus analyst price target of $75.40. Despite recent earnings beats in Q3 and Q4 2025, the company reported a net loss of -$21.02M in 2025, with profitability metrics like ROE at -30.42% reflecting operational challenges. The stock faces headwinds from a securities class action lawsuit alleging fraud, as noted in multiple legal alerts from July 2026.
The outlook is mixed: strong analyst buy ratings (90.91%) suggest upside potential, but negative margins and legal risks pose significant threats. Investors should weigh the high valuation multiples, such as EV/EBITDA of 161.17, against growth prospects in the genomics sector, with cash flow trends showing volatility into 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACM Research Inc
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
